What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
about
Idelalisib for the treatment of non-Hodgkin lymphoma.Chronic lymphocytic leukemia (CLL)-Then and now.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyTargeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.
P2860
What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
What is the status of novel an ...... eave rituximab in the shadows?
@en
type
label
What is the status of novel an ...... eave rituximab in the shadows?
@en
prefLabel
What is the status of novel an ...... eave rituximab in the shadows?
@en
P2860
P1476
What is the status of novel an ...... eave rituximab in the shadows?
@en
P2093
Bruce D Cheson
Maria Chaudhry
P2860
P304
P356
10.1586/17474086.2015.1087844
P577
2015-09-14T00:00:00Z